Publisher
Springer Science and Business Media LLC
Reference72 articles.
1. Sacks LV, Shamsuddin HH, Yasinskaya YI, Bouri K, Lanthier ML, Sherman RE. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA. 2014;311(4):378–84. https://doi.org/10.1001/jama.2013.282542.
2. Tyndall A, Du W, Breder CD. Regulatory watch: the target product profile as a tool for regulatory communication: advantageous but underused. Nat Rev Drug Discov. 2017;16(3):156. https://doi.org/10.1038/nrd.2016.264.
3. ICH harmonised guideline Drug Interaction Studies 24 May 2022. https://database.ich.org/sites/default/files/M12_Step1_draft_Guideline_2022_0524.pdf.
4. Bocci G, Oprea TI, Benet LZ. State of the art and uses for the biopharmaceutics drug disposition classification system (BDDCS): New additions, revisions, and citation references. AAPS J. 2022;24(2):37. https://doi.org/10.1208/s12248-022-00687-0.
5. Food and Drug Administration, Center for Drug Evaluation and Research, 207988Orig1s000 Summary Review Lesinurad. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207988Orig1s000SumR.pdf.